TGFB1 and cancer: Therefore, increased immune cell infiltration with TGF-β inhibitors might promote sensitivity to anti-PD-1/PD-L1 immune checkpoint therapy and be particularly useful for treating TGF-β-enriched cancers in the stroma [94].